ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Astrazeneca and Lexicon’s type 1 diabetes fortunes diverge, for now
Astrazeneca gets one over on Sanofi and Lexicon with European approval for Forxiga. US regulators might not be so forgiving.
Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Ketoacidosis worries could scupper Lexicon
US approval of Lexicon and Sanofi’s SGLT inhibitor in type 1 diabetes hangs in the balance after an adcom tie.
FDA’s flashing green light boosts novel drug approvals
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.